Patricia Kaazan

ORCID: 0000-0003-0892-0680
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Mobile Health and mHealth Applications
  • Gastric Cancer Management and Outcomes
  • Cancer Research and Treatments
  • Health Systems, Economic Evaluations, Quality of Life
  • Bacteriophages and microbial interactions
  • Neuroendocrine Tumor Research Advances
  • Gastrointestinal Tumor Research and Treatment
  • Pancreatic and Hepatic Oncology Research
  • Central Venous Catheters and Hemodialysis
  • Eosinophilic Esophagitis
  • Health Literacy and Information Accessibility
  • Medical Coding and Health Information
  • Helicobacter pylori-related gastroenterology studies
  • Dialysis and Renal Disease Management
  • Lung Cancer Research Studies
  • Restraint-Related Deaths
  • COVID-19 Clinical Research Studies
  • Genetic factors in colorectal cancer
  • Healthcare Systems and Technology
  • Diverticular Disease and Complications
  • Pancreatitis Pathology and Treatment
  • Mycobacterium research and diagnosis
  • Gallbladder and Bile Duct Disorders

The University of Adelaide
2020-2024

Princess Alexandra Hospital
2021-2023

The University of Queensland
2022-2023

South Australian Health and Medical Research Institute
2023

Royal Adelaide Hospital
2020-2022

Logan Hospital
2020-2021

Queensland Health
2021

Health Net
2020

Central Adelaide Local Health Network
2020

Christ University
2020

Abstract Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment. Here, first, we demonstrate selective colonization of adenomas after oral delivery probiotic E. coli Nissle 1917 (EcN) a genetically-engineered murine model CRC predisposition orthotopic models CRC. We next undertake an interventional, double-blind, dual-centre, prospective clinical trial, in which patients take either placebo or EcN for two weeks prior resection...

10.1038/s41467-024-44776-4 article EN cc-by Nature Communications 2024-01-20

Crohn’s disease (CD) is an immune-mediated, multisystem inflammatory disorder characterised by discontinuous transmural, sometimes granulomatous, inflammation of the gastrointestinal tract. Although it can occur anywhere in tract, has a 70% predilection for terminal ileum. Ileocolonoscopy with biopsy remains gold standard initial diagnosis and assessment CD activity but several limitations, including invasiveness, risk complications cost. With shifting focus towards treatment targets...

10.1136/flgastro-2024-102971 article EN Frontline Gastroenterology 2025-02-23

Obesity is prevalent in the inflammatory bowel disease (IBD) population, particularly newly developed countries where both IBD and obesity general population are on rise. The role of pathogenesis was entertained but results from available studies conflicting. It does, however, appear to negatively influence course whilst impacting our medical surgical therapies. pro-inflammatory profile visceral adipose tissue might play a Crohn's Disease (CD). Interestingly, isolating mesentery anastomosis...

10.3390/biomedicines11123256 article EN cc-by Biomedicines 2023-12-08

Deliberate foreign body ingestion (DFBI) is characterised by recurrent presentations among patients with mental health conditions, intellectual disabilities and in prisoners. We aimed to profile the characteristics evaluate care of such this study.Adult an endoscopic record attempted retrieval between January 2013 September 2020 were identified at three Australian hospitals. Those a documented diagnosis included their standard medical records reviewed. Presentation history, demographics,...

10.1177/10398562231189431 article EN cc-by-nc Australasian Psychiatry 2023-07-20

Biologic therapies are effective at inducing and maintaining remission in people with inflammatory bowel disease (IBD). Previous studies have associated TNF-a inhibitors weight gain, however, it is unclear if this a class-specific effect or manifestation of good control. To clarify issue, retrospective study was undertaken to examine changes over time during therapy different biologic agents.Adult patients IBD who received any biological for least 12 months, between 2008 2020, were...

10.1007/s10620-022-07488-7 article EN cc-by-nc Digestive Diseases and Sciences 2022-04-03

Abstract Bioengineered probiotics enable new opportunities to improve colorectal cancer (CRC) screening, prevention and treatment strategies. Here, we demonstrate the phenomenon of selective, long-term colonization adenomas after oral delivery probiotic E. coli Nissle 1917 (EcN) a genetically-engineered murine model CRC predisposition. We show that, administration, can be monitored over time by recovering EcN from stool. also specific solitary neoplastic lesions in an orthotopic CRC. then...

10.1101/2023.04.03.535370 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2023-04-05

There is an increasing prevalence of chronic disease worldwide, resulting in multiple management challenges. Inflammatory bowel (IBD) exemplar requiring coordinated longitudinal care. We propose that Crohn's Colitis Care (CCCare), a novel IBD-specific, structured electronic medical record effective at improving data capture and acceptable to patients.A comparison was made between IBD-data completeness usual records CCCare. CCCare's acceptability patients assessed two independent IBD patient...

10.1002/jgh3.12631 article EN JGH Open 2021-08-07

Abstract Background Catheter‐related bloodstream infections (CRBSIs) in patients receiving home parenteral nutrition (HPN) for chronic intestinal failure (CIF) are associated with significant morbidity and financial costs. Taurolidine is a reduction infections, limited information on the cost‐effectiveness as primary prevention. This study aimed to determine of using taurolidine‐citrate prevention CRBSIs within quaternary hospital. Methods All CIF HPN were identified between January 2015...

10.1002/jpen.2589 article EN Journal of Parenteral and Enteral Nutrition 2023-12-08

Abstract Association between tumour necrosis alpha inhibitors and weight gain has been reported. We examined change in our cohort of inflammatory bowel disease patients treated with infliximab (IFX) for over 12 months, its associations financial implications. Two‐thirds gained during the course therapy. The mean after months IFX therapy was 3.3 (±6.5) kg.

10.1111/imj.14987 article EN Internal Medicine Journal 2020-09-01

10.1111/imj.14868 article EN Internal Medicine Journal 2020-06-01

of the following objectives: (1) to implement and pilot a national, cloud-based, EMR for IBD; (2) demonstrate this IBDspecific works in routine clinical care is able simultaneously populate research registry without duplicate data entry; (3) ascertain current unmet need more effectively delivered IBD therapy as defined by proportion patients specialist with active disease; or (4) provide an accurate picture severity, therapy, complications real-world cohort under usual at 2 large...

10.5217/ir.2022.00003 article EN cc-by-nc Intestinal Research 2022-04-25

Iron deficiency anemia is a common gastroenterological presentation. Endoscopic investigation standard practice. We describe case of iron in patient who was lost to follow‐up, before representing with clinically significant overt gastrointestinal bleeding, leading diagnosis metastatic small bowel neuroendocrine tumor. Early can lead curative surgical management. young man red flag and warrants thorough investigation.

10.35248/2165-8048.21.s4.001 article EN Internal Medicine Open Access 2021-01-01

Abstract Background Biologic therapies are effective at inducing and maintaining remission in patients with inflammatory bowel disease (IBD). Previous studies have associated TNF-a inhibitors weight gain, however it is unclear if this a class-related effect or manifestation of clinical remission. We performed retrospective study to compare changes from baseline across different biological classes, examine patterns over time assess characteristics associations within each (sub)groups. Methods...

10.1093/ecco-jcc/jjab076.491 article EN Journal of Crohn s and Colitis 2021-05-01

Abstract Background There is an increasing prevalence of chronic disease worldwide, resulting in multiple management challenges. Inflammatory bowel (IBD) exemplar requiring optimal longitudinal coordinated care. We propose that Crohn’s Colitis Care (CCCare), a novel IBD-specific electronic medical record intended to improve IBD care effective and acceptable patients. aimed assess both the effectiveness CCCare for data capture patients’ acceptability CCCare. Methods Methods: The study was...

10.1093/ecco-jcc/jjab076.358 article EN Journal of Crohn s and Colitis 2021-05-01
Coming Soon ...